RESPIRATORY SYNCYTIAL VIRUS

  • The Food and Drug Administration (FDA) approved the first vaccine, Arexvy for respiratory syncytial virus (RSV) to lower respiratory tract disease in people older than 60 years.
  • This is the first RSV vaccine to be approved anywhere in the world.
  • The trial showed that a single dose of the vaccine reduced the risk of people, older than 60 years, developing lower respiratory tract disease caused by the RSV virus by 82.6% and reduced the risk of developing severe disease by 94.1%.
  • Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms.
  • RSV can be serious, especially for infants and older adults.
  • RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age.
  • Respiratory syncytial virus (RSV) causes infections of the lungs and respiratory tract.

SOURCE: THE HINDU, THE ECONOMIC TIMES, PIB

About sree nivas

Check Also

thota

The Transplantation of Human Organs and Tissues Act (THOTA)

Concept The Transplantation of Human Organs and Tissues Act (THOTA) was enacted in India in …

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Free Updates to Crack the Exam!
Subscribe to our Newsletter for free daily updates